Clinical Trial Update: Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication [Phase 2]

View source ↗

Summary

Phase 2 trial of Ad2/HIF-1α/VP16 gene transfer for intermittent claudication (peripheral artery disease) completed, reporting safety and efficacy findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Peripheral Artery Disease

Drugs mentioned

• Ad2/HIF-1α/VP16 gene transfer

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Intermittent Claudication, Peripheral Vascular Disease | Phase 2 | Status: COMPLETED